AI Score

Unlock

Repare Therapeutics Inc. (RPTX)

AI Score

Unlock

1.18

0.00 (0.00%)

At close: Mar 03, 2025, 3:59 PM

1.16

-1.69%

After-hours: Mar 03, 2025, 04:00 PM EST

No 1D chart data available

Bid	1.15
Market Cap	50.16M
Revenue (ttm)	66.62M
Net Income (ttm)	-84.16M
EPS (ttm)	-1.99
PE Ratio (ttm)	-0.59
Forward PE	-0.46
Analyst	Buy

Ask	1.3
Volume	242,403
Avg. Volume (20D)	488,700
Open	1.17
Previous Close	1.18
Day's Range	1.13 - 1.23
52-Week Range	1.06 - 7.28
Beta	0.87

About RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an ora...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 19, 2020

Employees 179

Stock Exchange NASDAQ

Ticker Symbol RPTX

Website https://www.reparerx.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for RPTX stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 493.22% from the latest price.

Buy 66.67%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Earnings Surprise

New

Repare Therapeutics has released their quartely earnings on Mar 3, 2025:

Revenue of $0 misses estimates by $2.73M, with -100.00% YoY decline.

EPS of -0.67 exceeds estimates by 0.12, with 0.00% YoY growth.

Next Earnings Release

Repare Therapeutics Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-55.42%

Repare Therapeutics shares are trading lower after... Unlock content with Pro Subscription

5 months ago

+0%

Repare Therapeutics shares are trading higher after the company announced it will present its Phase 1 data highlighting Camonsertib in combination with radiotherapy treatment at the ASTRO annual meeting

News

1 day ago · businesswire.com

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results.

1 month ago · zacks.com

Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Repare Therapeutics (RPTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions coul...

1 month ago · zacks.com

Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Repare Therapeutics (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i...

1 month ago · businesswire.com

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions.

2 months ago · benzinga.com

Why Is Repare Therapeutics Stock Trading Lower On Friday?

On Thursday, Repare Therapeutics Inc RPTX revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cance...

2 months ago · businesswire.com

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph1 Gynecologic Expansion Clinical Trial.

2 months ago · businesswire.com

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial.